Radiopharm Theranostics RADX
NASDAQ RADX
$2.15 +0.09 (+4.36%)
As of: Sep 10, 2026 · 10:29 AM EDT

Radiopharm Theranostics Ltd (RADX) EBIT Margin (2024 - 2026)

Radiopharm Theranostics' (RADX) quarterly EBIT Margin came in at 293.49% in Q2 2026, up 5606543.0% year-over-year from N/an in Q2 2025, and up 99.48% quarter-over-quarter from 56358.92% in Q2 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Radiopharm Theranostics Ltd (RADX) EBIT Margin (2024 - 2026) Analysis & Trends

Radiopharm Theranostics (RADX) has reported EBIT Margin for 3 consecutive years, with 293.49% the latest figure, recorded in Q2 2026.

Peer Set

Peer Comparison

All peers
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -293.49%
Jun 30, 2025 -56,358.92%
Jun 30, 2024 -111.24%